You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Crohn's disease

    SBC: TRIANGLE THERAPEUTICS INC.            Topic: 300

    PROJECT SUMMARY Crohn’s disease (CD) is a chronic autoimmune disease in which cells of the immune system attack gut tissue leading to diarrhea, fatigue, pain, and weight loss. CD affects up to one million Americans and is a type of inflammatory bowel disease. CD is driven by CD4 T cells with a significant role for TH1 and TH17 cells and additional involvement of B cells. Current therapies for CD ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Evaluation of recombinant bovine lactoferrin and N-linked glycan effects on infant gut health and immunity

    SBC: TURTLETREE LABS INC.            Topic: NICHD

    Project Summary/Abstract Most infants currently rely on infant formula (IF) to meet their nutritional needs. However, existing infant formula is functionally inferior because it lacks breast milk bioactive proteins that are crucial to infant health and development. Consequently, formula-fed infants have increased risk of morbidity and mortality. Current technology limits the ability to add bioacti ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Low Cost W-Band Imaging Array

    SBC: MILLIMETER WAVE SYSTEMS LLC            Topic: CBD22BT001

    Low-cost systems operating at video rates within W-band have remained elusive – especially for stand-off and remote applications. Real time video rate imaging requires parallel detection modalities that traditionally led to high costs and calibration challenges. Substantial advances in low-cost packaging and chip-level integration driven by commercial millimeter-wave applications can now be appl ...

    STTR Phase I 2023 Department of DefenseOffice for Chemical and Biological Defense
  4. Low Cost Imaging In The mm Wave Region Using Plasma Waves in High Mobility Transistor

    SBC: BRIMROSE TECHNOLOGY CORP            Topic: CBD22BT001

    In this work, we propose to develop low-cost, high sensitivity high electron mobility transistor-based W-band millimeter wave focal plane array/camera based on mature ternary III-V epitaxial materials of InAlAs on top of InP substrate. The plasma-wave detector uses well established mature technology of high electron mobility transistors which allows future integration and reduces cost. The detecto ...

    STTR Phase I 2023 Department of DefenseOffice for Chemical and Biological Defense
  5. Small molecule inhibitors of influenza virus nucleoprotein

    SBC: ALEXANDER BIODISCOVERIES, LLC            Topic: NIAID

    Influenza is a continuing worldwide public health threat, with seasonal activity that is not adequately controlled by the yearly vaccine program. The severity of this problem is likely to increase with emergence of new influenza virus strains in the human population, and this situation is made even more complex by the COVID-19 pandemic. Both COVID-19 and the 2009 H1N1 influenza pandemics are remin ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  6. Development of Small Molecule Antagonists of PAR-2 for treatment of asthma

    SBC: PARMEDICS, INC            Topic: NHLBI

    ABSTRACT: Current treatments for asthma largely are aimed at reducing exacerbations by directly treating airway inflammation. While successful in a subset of patients, asthma exacerbations remain a significant cause of morbidity and mortality and can result in airway injury, lung function decline and death. Exacerbations in more severe asthmatics are of particular concern, as health care costs and ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  7. Protease-activated-receptor-2 antagonists for treatment of migraine pain

    SBC: PARMEDICS, INC            Topic: 106

    PROJECT SUMMARY Migraine affects over 36 million people in the US, particularly those of working age (18-55 years), negatively impacting workplace productivity and presenting an enormous healthcare burden. For almost half of those who suffer from migraine, current treatments fail to provide relief and have limited ability to reverse pain once it has started. The most effective medications either r ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Development of small molecule Protease-activated-receptor-2 antagonists as oral asthma therapeutics

    SBC: PARMEDICS, INC            Topic: NHLBI

    Lay Abstract: Asthma is a widely prevalent condition that affects 1 in 12 adults in the United States and an estimated 300 million individuals worldwide. Mild asthma is well controlled by current standard of care (SOC), including long-acting b-adrenergic receptor agonists, anti- leukotrienes and/or inhaled corticosteroids. As patients progress to severe disease add-on treatment options can include ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Flexible Ion-Mediated Artificial Retina

    SBC: LAMBDAVISION INCORPORATED            Topic: NEI

    DESCRIPTION (provided by applicant): A flexible, protein-based, ion-mediated retinal implant is proposed for the restoration of vision for patients with retinal degenerative diseases, such as age-related macular degeneration (AMD) and retinitis pigmentosa(RP). The implant under development uses the retinal- containing protein, bacteriorhodopsin (BR), to convert light into a pH gradient. This gradi ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Antibacterial nanoparticles as insecticide synergists and insect growth regulators for improved control of cockroach infestations

    SBC: APEX BAIT TECHNOLOGIES, INC.            Topic: NIAID

    PROJECT SUMMARY The prevalence of asthma in the United States is approximately 8% (andgt;25 million people). In African Americans, the prevalence is andgt;11%. A majority of asthma sufferers are sensitized to allergens, including those shed in the feces, saliva, and exuviae of cockroaches. Thus, exposure to cockroach infestation is recognized as both a significant risk factor for the development o ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government